Ipsen: Acquisition, slowed erosion of Somatuline, and [accelerated sales] of the remaining product portfolio!
Reading Time: 2 minutes
Ipsen S.A. draws attention on October 22 with two news items. On one hand, the acquisition of ImCheck Therapeutics has been announced, aiming to expand its leadership position in oncology and strengthen its pipeline. The acquisition brings the first-in-class Phase I/II drug ICT01 into Ipsen's oncology pipeline. An agreed purchase price of 350 million euros has been set, along with contingent payments dependent on achieving regulatory and revenue-dependent milestones. The total potential consideration amounts to up to one billion euros....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
